Sautter BM, Wessely R, Bihl H.
Comparison of systemic radiotherapy with I-131-labeled monoclonal antibody BW575/9 to external beam radiotherapy in human neuroblastoma xenografts.
Strahlenther Onkol 1993;169:595-600.

Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber S.
A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3.

Schwarz EM, Badorff C, Hiura TS, Wessely R, Badorff A, Verma IM, Knowlton KU.
NF-kappaB-mediated inhibition of apoptosis is required for encephalomyocarditis virus virulence: a mechanism of resistance in p50 knockout mice.

Low-level expression of a mutant coxsackieviral cDNA induces a myocytopathic effect in culture: an approach to the study of enteroviral persistence in cardiac myocytes.

Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy.

Wessely R, Klingel K, Knowlton KU, Kandolf R.
Cardioselective Infection With Coxsackievirus B3 Requires Intact Type I Interferon Signaling : Implications for Mortality and Early Viral Replication.

Transcriptome analysis reveals a role of interferon-gamma in human neointima formation.

A central role of interferon regulatory factor-1 for the limitation of neointimal hyperplasia.

Transplantation. 2003;76:1470-1474.
Wessely R.
Coxsackieviral replication and pathogenicity: lessons from gene modified animal models.

Wessely R, Paschalidis M, Wagenpfeil S, Wegener F, Neumann FJ, Theiss W.
A comprehensive approach to visual and functional assessment of experimental vascular lesions in vivo.

Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: implications for the applicability on drug eluting stents to prevent neointima formation following vascular injury.

Cytomegalovirus and progressing heart transplant vasculopathy: enough evidence that needs to be translated in appropriate screening and treatment regimens.
Transplantation. 2004;78:632-633

Wessely R, Vorpahl M, Schömig A, Klingel K.
Late constrictive involvement of the pericardium in a case of previous myocarditis.

Wessely R, Seidl S, Schömig A.
Cardiac involvement in Emery-Dreifuss muscular dystrophy.

Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple and on-site stent coating.

Circulation. 2005;111:1583-1592

Wessely R.
Interference by interferons: Janus faces in vascular proliferative diseases.

Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating.
Eur Heart J. 2005;26(15):1475-81


Merl S, Wessely R. Anti-coxsackieviral efficacy of RNA interference is highly dependent on genomic target selection and emergence of escape mutants. Oligonucleotides. 2007;17:44-53


Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design.

Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis.

Differential healing response in polymer vs. non-polymer based sirolimus eluting stents.
JACC Cardiovasc Interv, 2008;1:535-544

The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts.
Biomaterials, 2009;30(4):632-7

Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention.
Circ Cardiovasc Interv, 2009;5:430-7

Wessely R.
New drug-eluting stent concepts.
Nat Rev Cardiol, 2010;4:194-203

Wessely R., Reddan D.
Contrast media, cardiovascular interventions and kidney injury: does contrast osmolarity matter?
Eur Nephrol, 2010;4:62-67

Wessely R. A
throsclerosis and cell cycle – put the brakes on! Critical role for cyclin-dependent kinase inhibitors.
J Am Coll Cardiol, 2010;55:2269-71

Merl S., Wessely R.
RNA interference to treat enteroviral disease: current status and clinical perspectives.
Curr Mol Ther, 2010;10:550-64
Wessely R. I
Initial experience with an institutional bridging protocol for patients with recent coronary stent implantation requiring discontinuation of dual antiplatelet therapy due to urgent surgery.
Am J Ther, 2011:280-282

Poll LW, Sadra B, Rühlow S, Wessely R.
Thrombosis of a large saphenous vein graft aneurysm leading to acute myocardial infarction 21 years after coronary artery bypass grafting: role of cardiac multi-slice computed tomography.

Wessely R, Andres V.
Limus is not limus – a proposal to adjust terminology in the context of drug-eluting stents.
J Cardiovasc Pharmacol 2012;59:485-86

Cardiogoniometry as a diagnostic tool in patients with acute coronary syndromes. Results of the CGM@ACS trial.
Clin Res Cardiol 2012;101:727-36

Comparison of Cardiogoniometry and electrocardiography with perfusion cardiac magnetic resonance imaging and late gadolinium enhancement.
Europace 2012

Wessely R.

Long-term follow-up of coronary venous bypass graft lesions treated with a new generation drug-eluting stent with bioabsorbable polymer.


Buchbeiträge (Auswahl)


